In vitro and in vivo evaluations of human papillomavirus type 16 (HPV16)-derived peptide-loaded dendritic cells (DCs) with a CpG oligodeoxynucleotide (CpG-ODN) adjuvant as tumor vaccines for immunotherapy of cervical cancer
/in Cervical Cancer, Dendritic Cells, International Publications /von 2013-08-03 / Arch. Gynecol. Obstet. 2014 Jan;289(1):155-62Neoadjuvant chemotherapy followed by radiotherapy and concurrent hyperthermia in patients with advanced-stage cervical cancer: a retrospective study
/in Cervical Cancer, Hyperthermia, International Publications /von 2012-06-12 / Int J Hyperthermia 2012;28(6):554-61[Study on the specific immunity induced by dendritic cell vaccine loading allogenic microvascular endothelial cell bEnd.3 antigen against U14 cervical cancer cell in mice]
/in Cervical Cancer, Dendritic Cells, International Publications /von 2011-01-01 / Zhonghua Fu Chan Ke Za Zhi 2011 Jan;46(1):52-7Effect of hyperthermia on the apoptosis and proliferation of CaSki cells
/in Cervical Cancer, Hyperthermia, International Publications /von 2010-11-30 / Mol Med Rep 2011 Jan-Feb;4(1):187-91Combined use of hyperthermia and radiation therapy for treating locally advanced cervix carcinoma
/in Cervical Cancer, Hyperthermia, International Publications /von 2010-03-17 / Cochrane Database Syst Rev 2010 Mar;(3):CD006377Hyperthermia dose-effect relationship in 420 patients with cervical cancer treated with combined radiotherapy and hyperthermia
/in Cervical Cancer, Hyperthermia, International Publications /von 2009-04-08 / Eur. J. Cancer 2009 Jul;45(11):1969-78Radiotherapy and hyperthermia for treatment of primary locally advanced cervix cancer: results in 378 patients
/in Cervical Cancer, International Publications /von 2008-11-05 / Int. J. Radiat. Oncol. Biol. Phys. 2009 Jan;73(1):242-50Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial
/in Cervical Cancer, Dendritic Cells, International Publications /von 2007-12-05 / J Virol 2008 Feb;82(4):1968-79RF-power and temperature data analysis of 444 patients with primary cervical cancer: deep hyperthermia using the Sigma-60 applicator is reproducible
/in Cervical Cancer, International Publications /von 2007-12-01 / Int J Hyperthermia 2007 Dec;23(8):623-43
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de